Agilvax, Inc.

DUBLIN, June 14, 2022 /PRNewswire/ -- The "Global Vaccine Partnering Terms and Agreements 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 1100 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Trends in vaccine and adjuvant partnering deals Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccines The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals. The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made. One of the key highlights of the report is that over 1100 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends. Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field. By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it. Global Vaccine Partnering Terms and Agreements 2014-2022: Deal trends, players and financials includes: Trends in vaccine dealmaking in the biopharma industry since 2014 Access to headline, upfront, milestone and royalty data Access to over 1100 vaccine deal documents The leading vaccine deals by value since 2014 Most active vaccine dealmakers since 2014 The leading vaccine partnering resources Available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Therapy target Specific technology type Analyzing actual contract agreements allows assessment of the following: What are the precise vaccine rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Vaccines dealmaking 2.1. Introduction 2.2. Vaccines partnering over the years 2.3. Most active Vaccines dealmakers 2.4. Vaccines partnering by deal type 2.5. Vaccines partnering by therapy area 2.6. Deal terms for Vaccines partnering 2.6.1 Vaccines partnering headline values 2.6.2 Vaccines deal upfront payments 2.6.3 Vaccines deal milestone payments 2.6.4 Vaccines royalty rates Chapter 3 - Leading Vaccines deals 3.1. Introduction 3.2. Top Vaccines deals by value Chapter 4 - Most active Vaccines dealmakers 4.1. Introduction 4.2. Most active Vaccines dealmakers 4.3. Most active Vaccines partnering company profiles Chapter 5 - Vaccines contracts dealmaking directory 5.1. Introduction 5.2. Vaccines contracts dealmaking directory Chapter 6 - Vaccines dealmaking by technology type Appendices Appendix 1 - Vaccines deals by company A-Z Appendix 2 - Vaccines deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Vaccines deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Appendix 4 - Vaccines deals by therapy area Anaesthetics Cardiovascular Central Nervous System Dental Gastrointestinal Hematology Immunology Infectives Metabolic Musculoskeletal Oncology Ophthalmics Orphan disease Pediatrics Psychiatry Respiratory Appendix 5 -Deal type definitions Appendix 6 - Further reading on dealmaking Companies Mentioned 2A 3D Medicines 3SBio 4D Pharma A*STAR' Institute of Molecular and Cell Biology ABEC ABIVAX AGC Biologics Agenus Bio Agilvax AIM ImmunoTech Akers Biosciences Amyris Analytical Bio-Chemistry Laboratories AnGes MG Anixa Biosciences Battelle Batu Biologics CCT Research Celldex Therapeutics Cellular Biomedicine Celonic Diavax Biosciences Diaxonhit DNA Script DNAtrix Dr. Reddy's Laboratories Frederick National Laboratory For Cancer Research Fred Hutchinson Cancer Research Center Fujifilm GISCAD Foundation GlaxoSmithKline Hefei Sageland Biotechnology Helmholtz Zentrum Munchen MinervaX Recipharm Sanofi Wyss Institute Xenetic Biosciences XstalBio Y-Biologics Y-mAbs Therapeutics Yale University Yamaguchi University Yisheng Biopharma Zenoaq Zoetis Zolovax Zuellig Pharma China Zydus Cadila ZYUS Life Sciences For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

June 13, 2022 12:00 UTC Joseph M. Patti, Ph.D., Appointed President and CEO John J. Kaiser, Retires as CEO, Remains as Board Director RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed President and Chief Executive Officer and a member of Evecxia’s board of directors. Dr. Patti brings extensive drug development and executive leadership expertise, including serving in multiple CEO roles, and as co-founder, Chief Scientific Officer and Senior Vice President of Research & Development of Inhibitex, Inc. until its $2.5 billion acquisition by Bristol Myers Squibb. Dr. Patti succeeds John J. Kaiser, who has retired but will continue to serve as a member of Evecxia’s board of directors. “We are delighted to have Dr. Patti join Evecxia at this exciting stage of development. Joe is a seasoned drug development executive with a proven track record in leading both private and public biopharmaceutical companies and generating significant shareholder value,” said Thomas H. Aasen, independent board member of Evecxia. “We believe he has an ideal combination of experience and leadership skills to advance Evecxia to the next level of development and growth. On behalf of the entire board, I also want to thank John Kaiser for his years of dedicated service and tireless effort to position Evecxia with two differentiated, first-in-class drug candidates. We are pleased to retain John’s corporate development and strategic commercial expertise as a member of our board and look forward to his continued contributions.” Dr. Patti has over two decades of drug development experience in the biopharmaceutical industry and has been a successful entrepreneur and scientific leader. He currently is a member of the board of directors of Armata Pharmaceuticals and served as President of JP Biotech Advisors, where he provided strategic growth, financing and drug development guidance to emerging biotechnology companies. Previously, he was President and Chief Executive Officer at AgilVax, Inc. and Aviragen Therapeutics. Prior to joining Aviragen, he co-founded Inhibitex, Inc. and served as its Chief Scientific Officer and Senior Vice President of Research & Development until it was acquired by Bristol Myers Squibb. Earlier, Dr. Patti was an Assistant Professor at Texas A&M’s Institute of Biosciences and Technology and served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, a M.S.P.H. from the University of Miami, School of Medicine, and a Ph.D. in Biochemistry from the University of Alabama at Birmingham. Dr. Patti, President and Chief Executive Officer added: "Evecxia has established an impressive foundation with two clinical stage programs built around unique technologies that enables the therapeutic potential of 5-hydroxytryptophan (5-HTP) and serotonin synthesis amplification. I look forward to working with the Evecxia team to realize the full potential of these technologies and clinical programs to make a meaningful difference in the lives of patients suffering from disabling brain disorders.” About Evecxia Therapeutics, Inc. Evecxia Therapeutics is a privately funded, clinical stage pharmaceutical company, located in Research Triangle Park, NC. Evecxia’s mission is to help treat patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate and sub-optimal. Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat disorders of the brain. Evecxia has two clinical stage drug candidates in development, EVX-101 is being developed as an adjunctive treatment, when first line antidepressants alone are inadequate, and EVX-301 is being developed as a rescue therapy in acute suicidal crisis. Evecxia has licensed a comprehensive portfolio of issued and pending patents on the 5-HTP slow-release/serotonin amplification method, formulations, and related technologies from Duke University, the National University of Singapore through its Duke-NUS Medical School, National University Hospital and Nanyang Technological University, Singapore (NTU Singapore). For additional information about the Evecxia, please visit .